Search results
Results From The WOW.Com Content Network
Moderna was founded in 2010 by Derrick Rossi, Timothy A. Springer, Kenneth R. Chien, Robert S. Langer, and Noubar Afeyan. [9] Stéphane Bancel , the current CEO, was appointed as CEO in 2011. [ 6 ] [ 10 ] Between 2011 and 2017, Moderna raised $2 billion in venture capital funding.
The Moderna news followed preliminary results from the Pfizer-BioNTech vaccine candidate, BNT162b2, with Moderna demonstrating similar efficacy, but requiring storage at the temperature of a standard medical refrigerator of 2–8 °C (36–46 °F) for up to thirty days or −20 °C (−4 °F) for up to four months, whereas the Pfizer-BioNTech ...
How COVID‑19 vaccines work. The video shows the process of vaccination, from injection with RNA or viral vector vaccines, to uptake and translation, and on to immune system stimulation and effect. Part of a series on the COVID-19 pandemic Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom. COVID-19 (disease) SARS-CoV-2 (virus) Cases Deaths ...
The Moderna COVID-19 vaccine, also known as Spikevax, [318] is an mRNA vaccine [319] produced by the American company Moderna, the U.S. National Institute of Allergy and Infectious Diseases, the U.S. Biomedical Advanced Research and Development Authority, and the Coalition for Epidemic Preparedness Innovations.
Before joining Moderna, Bancel was the CEO of French diagnostics company BioMérieux. Bancel is a partner at Flagship Pioneering, and has served on the boards of Indigo Agriculture, Boston's Museum of Science, and Qiagen. As of May 2023, his net worth was estimated at US$4.1 billion, owning about 8% of Moderna. [2]
Noubar Afeyan (Western Armenian: Նուպար Աֆէեան; born in 1962) is an American-Canadian entrepreneur, inventor, and philanthropist. [1] [2] He is best known for co-founding the biotechnology company Moderna, through his venture capital firm, Flagship Pioneering, and for co-founding humanitarian projects such as Aurora Prize and The Future Armenian.
Moderna was founded in 2010, based on discovery that pluripotent stem cells can be transformed and reprogrammed. [9] [10] Time magazine cited this pluripotent discovery as one of the top ten medical breakthroughs of the year. [11]
mRNA-1283 is a COVID-19 vaccine candidate developed by Moderna. [ 2 ] [ 3 ] Compared to prior mRNA vaccines, this candidate has a storage temperature of 2-5 °C, compatible with vaccine storage in a standard refrigerator, rather than low temperature freezers. [ 4 ]